Sihuan Pharmaceutical’s Breakthrough in Breast Cancer Treatment

The latest announcement is out from Sihuan Pharmaceutical Holdings Group ( (HK:0460) ).

Sihuan Pharmaceutical Holdings Group Ltd. announced significant results from a phase 3 clinical trial of its innovative drug Bireociclib, in combination with Fulvestrant, for treating HR+/HER2- advanced breast cancer. The study, published in Nature Communications, demonstrated that the combination therapy significantly improved progression-free survival compared to Fulvestrant alone, marking a notable advancement in treatment options for complex and refractory breast cancer cases. This achievement underscores Sihuan Pharmaceutical’s strong R&D capabilities and commitment to addressing unmet clinical needs, enhancing its position in the pharmaceutical industry.

More about Sihuan Pharmaceutical Holdings Group

Sihuan Pharmaceutical Holdings Group Ltd. is a pharmaceutical company with a focus on innovative drug development, particularly in areas such as oncology and digestion. Its subsidiary, Xuanzhu Biopharmaceutical, is dedicated to the research, development, production, and commercialization of class 1 drugs with proprietary intellectual property rights, leveraging both small molecule chemistry and large molecule biologics R&D platforms.

YTD Price Performance: -2.00%

Technical Sentiment Signal: Strong Buy

Current Market Cap: $672.7M

For a thorough assessment of 0460 stock, go to TipRanks’ Stock Analysis page.